To outline recent genetic engineering strategies that enhance the safety, durability, and efficacy of CAR-T cell therapy for solid tumors, addressing critical challenges.
Key Findings:
CAR-T therapy has shown remarkable success in hematologic cancers but faces significant challenges in solid tumors.
Innovative genetic engineering strategies can improve CAR-T cell safety and effectiveness, particularly in solid tumors.
Interdisciplinary approaches are crucial for overcoming limitations in CAR-T therapy and enhancing its clinical application.
Interpretation:
The integration of advanced engineering strategies can potentially broaden the clinical application of CAR-T therapy in solid tumors by effectively addressing critical challenges.
Limitations:
Clinical manufacturing and regulatory approval complexities pose significant barriers to implementation.
Economic sustainability of advanced CAR-T platforms remains a concern for widespread adoption.
Conclusion:
Innovative CAR-T cell engineering strategies hold promise for enhancing treatment outcomes in solid tumors, but practical challenges must be addressed to realize their full potential.
